This invention relates to novel probiotic Bifidobacteria strains, particularly, a B. pseudocatenulatum strain, and its use as probiotic, and food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of obesity, diabetes (particularly Type 2 diabetes), and related conditions.